Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Aripiprazol untuk skizofrenia stabil dalam layanan bersama

Penilaian teknologi kesehatan PTK-N05AX12 Draf untuk telaah Diperbarui 3 Agustus 2026

1. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
AripiprazolRp 64,0 juta3,3714,86
risperidonRp 41,7 juta3,3544,85
SelisihRp 22,3 juta0,017-

2. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
01020304050-0,10-0,050,000,050,10Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta1,4%

3. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-20-1001020interventions aripiprazole shared care annual drug cost idrinterventions aripiprazole shared ...interventions aripiprazole shared care transition rate multipliers stable psychosis to relapse hospitalinterventions aripiprazole shared ...interventions aripiprazole shared care transition rate multipliers stable psychosis to symptomatic psychosisinterventions aripiprazole shared ...interventions risperidone shared care transition rate multipliers stable psychosis to relapse hospitalinterventions risperidone shared c...transition rates annual relapse hospital to stable psychosistransition rates annual relapse ho...interventions risperidone shared care transition rate multipliers stable psychosis to symptomatic psychosisinterventions risperidone shared c...utility values metabolic complicationutility values metabolic complicat...annual care costs idr metabolic complicationannual care costs idr metabolic co...utility values stable psychosisutility values stable psychosistransition rates annual relapse hospital to metabolic complicationtransition rates annual relapse ho...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

4. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (5 yr)0,017Rp 22,3 jutaRp 1,3 miliar
0% discount rate0,019Rp 24,0 jutaRp 1,2 miliar
5% discount rate0,016Rp 21,3 jutaRp 1,3 miliar
Intervention price 50% below base case0,017Rp 11,0 jutaRp 636,2 juta
Intervention price 50% above base case0,017Rp 33,6 jutaRp 1,9 miliar
No relapse difference versus risperidone0,022Rp 22,1 jutaRp 1,0 miliar

5. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0000%).

Luaran pembandingPrediksi modelData terbitSumber
Annual symptomatic relapse probability under risperidone shared care18,0%18,0%CATIE-era active-antipsychotic discontinuation and relapse calibration.

6. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • KMK 1199/2025 Fornas status was re-audited for this indication and formulation through the official decision page: https://farmalkes.kemkes.go.id/unduh/keputusan-menteri-kesehatan-republik-indonesia-nomor-hk-01-07-menkes-1199-2025-tentang-formularium-nasional/
  • The searchable e-Fornas catalogue was cross-checked at: https://e-fornas.farmalkes.kemkes.go.id/guest/landing
  • Policy route: PRB specialist-initiated shared care. Does aripiprazole's lower metabolic burden justify its additional acquisition cost in stable shared care?
  • CATIE provides comparative effectiveness context for antipsychotic discontinuation and adverse effects: https://pubmed.ncbi.nlm.nih.gov/16172203/
  • WHO mhGAP 2023: https://www.who.int/publications/i/item/9789240084278